Get the Stockscreener App
3.7899
2.99%
0.1099
Clene Inc stock is traded at $3.7899, with a volume of 6,013.
It is up +2.99% in the last 24 hours and up +5.57% over the past month.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.
See More
Previous Close:
$3.68
Open:
$3.68
24h Volume:
6,013
Relative Volume:
0.06
Market Cap:
$31.33M
Revenue:
$442.00K
Net Income/Loss:
$-30.46M
P/E Ratio:
-0.8498
EPS:
-4.46
Net Cash Flow:
$-27.47M
1W Performance:
+1.33%
1M Performance:
+5.57%
6M Performance:
-17.25%
1Y Performance:
-25.10%
1-Day Range:
$3.6526
$3.7899
1-Week Range:
$3.535
$3.7922
52-Week Range:
$2.2801
$6.90
Clene Inc Stock (CLNN) Company Profile
Name
Clene Inc
Sector
Industry
Phone
801-676-9695
Address
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
3.7899 | 32.88M | 442.00K | -30.46M | -27.47M | -4.46 |
|
KHC
Kraft Heinz Co
|
27.36 | 32.26B | 25.43B | 2.66B | 3.03B | 2.19 |
|
JBS
Jbs N V
|
14.14 | 30.65B | 88.95B | 2.16B | 374.50M | 0.9748 |
|
K
Kellanova
|
80.11 | 27.76B | 12.63B | 1.38B | 863.00M | 3.96 |
|
GIS
General Mills Inc
|
49.36 | 26.75B | 19.64B | 2.56B | 2.48B | 4.55 |
|
MKC
Mccormick Co Inc
|
69.60 | 18.63B | 6.68B | 792.60M | 774.40M | 2.94 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-18-22 | Initiated | H.C. Wainwright | Buy |
| May-02-22 | Initiated | Canaccord Genuity | Buy |
| Sep-28-21 | Initiated | Oppenheimer | Outperform |
Clene Inc Stock (CLNN) Latest News
Clene (NASDAQ: CLNN) To Present At Canaccord 45th Annual Growth Conference - Barchart.com
Clene (NASDAQ: CLNN) to Present at Canaccord 45th Annual Growth Conference - The Globe and Mail
Watch for Trend Continuation in Clene Inc. Equity Warrant Next WeekSmart Allocation Growth Setup Plan - beatles.ru
MarketBeat All Access Sale Buy Now For Just $5 - MarketBeat
Clene Inc. to Present at Canaccord 45th Annual Growth Conference on August 12, 2025 - Quiver Quantitative
Clene to Present at the Canaccord 45th Annual Growth Conference - The Manila Times
ALS and MS Treatment Developer Clene to Reveal Latest Progress at Major Growth Conference - Stock Titan
Sentiment Turns Positive on Clene Inc. — Reversal AheadIntraday Trend Analysis for Fast Gains Released - metal.it
Why Clene Inc. Equity Warrant stock attracts strong analyst attentionConservative Entry for High Return Setup Backed - beatles.ru
What is the risk reward ratio of investing in Clene Inc. stockTriple-digit wealth increases - Jammu Links News
What analysts say about Clene Inc. Equity Warrant stockUnlock expert trading strategies for growth - Jammu Links News
What is Clene Inc. company’s growth strategyMassive profits - Jammu Links News
What is the dividend policy of Clene Inc. stockHigh-velocity capital appreciation - Jammu Links News
Is Clene Inc. a growth stock or a value stockUnprecedented profits - Jammu Links News
Is it the right time to buy Clene Inc. stockOutstanding trading profits - Jammu Links News
What markets is Clene Inc. expanding into Is MURA stock a good long term investment optionCapitalize on market momentum for maximum gains - Jammu Links News
What are analysts’ price targets for Clene Inc. Equity Warrant in the next 12 monthsBuild a portfolio that grows with the market - Jammu Links News
Why is Clene Inc. stock attracting strong analyst attentionDouble-digit growth - Jammu Links News
Is it the right time to buy Clene Inc. Equity Warrant stockRapid growth opportunities - Jammu Links News
How volatile is Clene Inc. Equity Warrant stock compared to the marketAccelerated wealth building - Jammu Links News
What drives Clene Inc. Equity Warrant stock priceCapitalize on high-yield stocks early - Jammu Links News
How does Clene Inc. Equity Warrant compare to its industry peersExceptional stock performance - Jammu Links News
What institutional investors are buying Clene Inc. stockFree Capital Allocation Plans - Jammu Links News
Clene (NASDAQ: CLNN) Reports CNM-Au8 Significantly Improves Survival in ALS Patients - The Globe and Mail
What are Clene Inc. Equity Warrant company’s key revenue driversOutperformance with explosive growth - Jammu Links News
Published on: 2025-08-03 11:24:38 - Jammu Links News
What are the technical indicators suggesting about Clene Inc.Explosive portfolio gains - Jammu Links News
Does Clene Inc. Equity Warrant stock perform well during market downturnsOutstanding investment returns - Jammu Links News
How many analysts rate Clene Inc. as a “Buy”Get real-time alerts on top-performing stocks - Jammu Links News
What drives Clene Inc. stock priceUnbelievable profit margins - Jammu Links News
Is Clene Inc. Equity Warrant a growth stock or a value stockDiscover stocks with strong growth potential - Jammu Links News
What is Clene Inc. Equity Warrant company’s growth strategyCapitalize on fast-growing stocks today - Jammu Links News
What catalysts could drive Clene Inc. Equity Warrant stock higher in 2025Invest smarter with actionable market insights - Jammu Links News
What are the latest earnings results for Clene Inc.Exceptional risk-adjusted gains - Jammu Links News
Published on: 2025-08-03 02:32:15 - Jammu Links News
Clene Inc. Equity Warrant Volume Confirms Breakout — Analysts BullishLow Risk Swing Trade Opportunities Identified - beatles.ru
Will Volume Confirm Reversal in Clene Inc.Community Verified Stock Suggestions Drive Volume - beatles.ru
What is the dividend policy of Clene Inc. Equity Warrant stockWealth Building Guidance For Smart Trading - jammulinksnews.com
Is Clene Inc. stock overvalued or undervaluedValue Investing Tracker To Watch Now - Jammu Links News
Clene Inc. expected to post a loss of 47 cents a shareEarnings Preview - TradingView
Statistical indicators supporting Clene Inc. Equity Warrant’s strengthHigh Yield Stock Screening Results Explained - metal.it
Order Book Volume Tilts Bullish on Clene Inc. Equity WarrantAccurate Technical Trend Reversal Picks Detected - metal.it
Clene Inc. Advances Toward FDA Approval for ALS Treatment CNM-Au8® - citybuzz -
Clene Inc. Reaches Critical Trendline SupportHigh Growth Low Risk Stock Selection Gets Analyst Nod - metal.it
Clene (NASDAQ: CLNN) Builds Momentum To Bring New Hope To Neuro Patients - Barchart.com
What are the technical indicators suggesting about Clene Inc. Equity WarrantTrack top-performing stocks in real-time - jammulinksnews.com
What is the risk reward ratio of investing in Clene Inc. Equity Warrant stockAccess powerful market insights for free - Jammu Links News
Clene Inc Stock (CLNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Clene Inc Stock (CLNN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| General Resonance LLC | 10% Owner |
Jun 02 '25 |
Sale |
4.12 |
600 |
2,473 |
708,592 |
| General Resonance LLC | 10% Owner |
May 30 '25 |
Sale |
2.80 |
410 |
1,148 |
709,192 |
| General Resonance LLC | 10% Owner |
May 29 '25 |
Sale |
2.73 |
410 |
1,119 |
709,602 |
| General Resonance LLC | 10% Owner |
May 28 '25 |
Sale |
2.60 |
420 |
1,090 |
710,012 |
| General Resonance LLC | 10% Owner |
May 27 '25 |
Sale |
2.45 |
420 |
1,029 |
710,432 |
| General Resonance LLC | 10% Owner |
Mar 19 '25 |
Sale |
4.40 |
1,400 |
6,160 |
710,852 |
| General Resonance LLC | 10% Owner |
Mar 18 '25 |
Sale |
4.45 |
1,333 |
5,932 |
712,252 |
| MATLIN DAVID J | Director |
Sep 30 '24 |
Buy |
4.75 |
92,307 |
438,458 |
444,491 |
| Mortenson Mark | Chief Science Officer |
Sep 30 '24 |
Buy |
4.75 |
20,512 |
97,432 |
28,949 |
| Etherington Robert Dee | Chief Executive Officer |
Sep 30 '24 |
Buy |
4.75 |
10,000 |
47,500 |
40,149 |
0.74%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):